趨化因子C-X-C-基元受體4(CXCR4)單克隆抗體
Monoclonal Antibody to Chemokine C-X-C-Motif Receptor 4 (CXCR4)
CD184; Fusin; NPYR; HSY3RR; LAP3; LCR1; LESTR; NPY3R; NPYRL; WHIM; Leukocyte-derived seven transmembrane domain receptor; Lipopolysaccharide-associated protein 3
- 編號MAA940Po21
- 物種Sus scrofa; Porcine (Pig，豬) 相同的名稱，不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(克隆號)-
- Ig亞型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 -
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 716 ¥ 1672 ¥ 2388 ¥ 5970 ¥ 23880
- 欲了解實際交易價格和更多情況，請與當地經銷商聯(lián)系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
通過ISO 9001、ISO 13485質量體系認證
特異性
該抗體是針對CXCR4的小鼠單克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別CXCR4。
用法
免疫印跡：0.2-2μg/mL;1:500-5000
免疫組織化學：5-20μg/mL;1:50-200
免疫細胞化學：5-20μg/mL;1:50-200
最佳稀釋倍數最終由用戶決定。
儲存
經常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
贈品
增值服務
相關產品
| 編號 | 適用物種：Sus scrofa; Porcine (Pig，豬) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA940Po01 | 趨化因子C-X-C-基元受體4(CXCR4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA940Po01 | 趨化因子C-X-C-基元受體4(CXCR4)多克隆抗體 | WB; IHC; ICC; IP. |
| MAA940Po21 | 趨化因子C-X-C-基元受體4(CXCR4)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA940Po | 趨化因子C-X-C-基元受體4(CXCR4)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA940Po | 趨化因子C-X-C-基元受體4(CXCR4)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| International Journal of Cancer | Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model [Wiley: source] |
| Plos one | Emodin Suppresses Migration and Invasion through the Modulation of CXCR4 Expression in an Orthotopic Model of Human Hepatocellular Carcinoma [PubMed: PMC3589458] |
| Atherosclerosis | The non-alcoholic fraction of beer increases stromal cell derived factor 1 and the number of circulating endothelial progenitor cells in high cardiovascular risk subjects: A randomized clinical trial [Pubmed:24530788] |
| Pharmacol Rep.? | Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression [Pubmed:25150002] |
| Pharmacological Reports | Serum concentrations of chemokines (CCL-5 and CXCL-12), chemokine receptors (CCR-5 and CXCR-4), and IL-6 in patients with posttraumatic stress disorder and avoidant personality disorder [PubMed: 26481549] |
| Pharmacological Reports | A study of chemokines, chemokine receptors and interleukin-6 in patients with panic disorder, personality disorders and their co-morbidity [Pubmed:27208878] |
| BMC Cancer.? | Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists [pmc:PMC4866076] |
| Frontiers in Bioengineering and Biotechnology | Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison?… [Pubmed:29670878] |
留言咨詢
